Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease

Nature Communications

Volumn 4, Issue , 2013, Pages

  Ueki, Nobuhide ^a   Lee, Siyeon ^a   Sampson, Nicole S ^a   Hayman, Michael J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOC KAC PURO; HISTONE DEACETYLASE; PRODRUG; PROTEINASE; UNCLASSIFIED DRUG;

AMINO ACID; CANCER; DRUG; ENZYME ACTIVITY; PROTEIN; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASM; NONHUMAN; TUMOR XENOGRAFT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSIN L; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; PRODRUGS; PUROMYCIN;

EID: 84889256327     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3735     Document Type: Article

References (40)

1. Witt, O., Deubzer, H. E., Milde, T. &Oehme, I. HDAC family: what are the cancer relevant targets? Cancer Lett. 277, 8-21 (2009).
2. Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L. &Olson, E. N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl Acad. Sci. USA 106, 7751-7755 (2009).
3. Bolden, J. E., Peart, M. J. &Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
4. Minucci, S. &Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (2006).
5. Marks, P. A. &Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell Biochem. 107, 600-608 (2009).
6. Wagner, J. M., Hackanson, B., Lubbert, M. &Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenet. 1, 117-136 (2010).
7. Lee, J. H., Choy, M. L., Ngo, L., Foster, S. S. &Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl Acad. Sci. USA 107, 14639-14644 (2010).
8. Bhaskara, S. et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18, 436-447 (2010).
9. Joyce, J. A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453 (2004).
10. Jedeszko, C. &Sloane, B. F. Cysteine cathepsins in human cancer. Biol. Chem. 385, 1017-1027 (2004).
11. Gonzalez-Suarez, I. et al. A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair. EMBO J. 30, 3383-3396 (2011).
12. Collette, J., Ulku, A. S., Der, C. J., Jones, A. &Erickson, A. H. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int. J. Cancer 112, 190-199 (2004).
13. Denhardt, D. T., Greenberg, A. H., Egan, S. E., Hamilton, R. T. &Wright, J. A. Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 2, 55-59 (1987).
14. Joseph, L. J., Chang, L. C., Stamenkovich, D. &Sukhatme, V. P. Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts. J. Clin. Invest. 81, 1621-1629 (1988).
15. Tian, Y., Bova, G. S. &Zhang, H. Quantitative glycoproteomic analysis of optimal cutting temperature-embedded frozen tissues identifying glycoproteins associated with aggressive prostate cancer. Anal. Chem. 83, 7013-7019 (2011).
16. Grotsky, D. A. et al. BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J. Cell Biol. 200, 187-202 (2013).
17. Goulet, B. et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 14, 207-219 (2004).
18. Goulet, B. et al. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol. Cancer Res. 5, 899-907 (2007).
19. Duncan, E. M. et al. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 135, 284-294 (2008).
20. Lankelma, J. M. et al. Cathepsin L, target in cancer treatment? Life Sci. 86, 225-233 (2010).
21. Glaser, K. B. et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310, 529-536 (2003).
22. Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455-463 (2004).
23. Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548-13558 (2006).
24. Choi, K. Y., Swierczewska, M., Lee, S. &Chen, X. Protease-activated drug development. Theranostics 2, 156-178 (2012).
25. Vecsey-Semjen, B. et al. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene 21, 4646-4662 (2002).
26. Oft, M. et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462-2477 (1996).
27. Yoshida, M., Kijima, M., Akita, M. &Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179 (1990).
28. Mariadason, J. M., Velcich, A., Wilson, A. J., Augenlicht, L. H. &Gibson, P. R. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology 120, 889-899 (2001).
29. Wegener, D., Wirsching, F., Riester, D. &Schwienhorst, A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 10, 61-68 (2003).
30. Bonfils, C. et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin. Cancer Res. 14, 3441-3449 (2008).
31. Khan, N. et al. Determination of the class and isoform selectivity of smallmolecule histone deacetylase inhibitors. Biochem. J. 409, 581-589 (2008).
32. Arts, J. et al. JNJ-26481585, a novel second-generation oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer Res. 15, 6841-6851 (2009).
33. Nebbioso, A. et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 10, 776-782 (2009).
34. Vara, J. A., Portela, A., Ortin, J. &Jimenez, A. Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance. Nucleic Acids Res. 14, 4617-4624 (1986).
35. Pestka, S., Rosenfeld, H., Harris, R. &Hintikka, H. Studies on transfer ribonucleic acid-ribosome complexes. XXI. Effect of antibiotics on peptidylpuromycin synthesis by mammalian polyribosomes. J. Biol. Chem. 247, 6895-6900 (1972).
36. Schmidt, E. K., Clavarino, G., Ceppi, M. &Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat. Methods 6, 275-277 (2009).
37. Bender, D. M. et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J. Med. Chem. 52, 6958-6961 (2009).
38. Cheon, E. P., Hong, J. H. &Han, H. K. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J. Pharm. Pharmacol. 58, 927-932 (2006).
39. Eigner, S. et al. Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin. Mol. Imaging Biol. 15, 79-86 (2013).
40. Starck, S. R., Green, H. M., Alberola-Ila, J. &Roberts, R. W. A general approach to detect protein expression in vivo using fluorescent puromycin conjugates. Chem. Biol. 11, 999-1008 (2004).